Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : NVAX crawled time : 15:00 save search
Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Published: 2024-02-28 (Crawled : 15:00) - biospace.com/
NVAX | $4.07 2.52% 2.93% 1.8M
|
Health Technology
|
| O: -22.92%
H: 1.29%
C: -4.96%
year financial results
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024
Published: 2024-02-20 (Crawled : 15:00) - biospace.com/
NVAX | $4.07 2.52% 2.93% 1.8M
|
Health Technology
|
| O: 0.0%
H: 1.68%
C: -0.72%
conference year financial results
Novavax to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Operational Highlights on November 9, 2023
Published: 2023-11-02 (Crawled : 15:00) - biospace.com/
NVAX | $4.07 2.52% 2.93% 1.8M
|
Health Technology
|
| O: -0.71%
H: 3.88%
C: 2.73%
conference financial results
Novavax to Host Conference Call to Discuss Second Quarter 2023 Financial Results and Operational Highlights on August 8, 2023
Published: 2023-08-01 (Crawled : 15:00) - biospace.com/
NVAX | $4.07 2.52% 2.93% 1.8M
|
Health Technology
|
| O: -1.51%
H: 1.59%
C: -4.27%
conference financial results
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
Published: 2023-02-13 (Crawled : 15:00) - biospace.com/
NVAX | $4.07 2.52% 2.93% 1.8M
|
Health Technology
|
| O: 1.42%
H: 1.9%
C: -2.4%
covid-19 vaccine
Novavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference
Published: 2022-12-02 (Crawled : 15:00) - biospace.com/
NVAX | $4.07 2.52% 2.93% 1.8M
|
Health Technology
|
| O: -2.08%
H: 0.33%
C: 0.12%
conference biotech
Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax COVID-19 Vaccine as a Primary Series for Adults Aged 18 and Older
Published: 2022-09-13 (Crawled : 15:00) - biospace.com/
NVAX | $4.07 2.52% 2.93% 1.8M
|
Health Technology
|
| O: -6.06%
H: 1.55%
C: -0.71%
covid-19 vaccine india africa
BioSpace Movers & Shakers, April 1
Published: 2022-04-01 (Crawled : 15:00) - biospace.com/
RCOR | $3.2 0.0%
|
|
| O: 0.0%
H: 3.19%
C: -4.01%
WMT | News | $60.14 1.03% 0.23% 12M
|
Retail Trade
|
| O: 0.5%
H: 1.08%
C: 0.9%
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: -0.64%
H: 0.6%
C: 0.57%
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: -1.39%
H: 0.0%
C: 0.0%
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: 0.22%
H: 1.01%
C: 0.86%
ABT | News | $107.07 -0.2% 0.18% 3.8M
|
Health Technology
|
| O: 0.41%
H: 0.11%
C: -0.22%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: 0.0%
NVAX | $4.07 2.52% 2.93% 1.8M
|
Health Technology
|
| O: -0.48%
H: 4.07%
C: 1.39%
NKTX | $7.39 1.37% 1.35% 730K
|
Health Technology
|
| O: -1.23%
H: 4.98%
C: 1.78%
ALEC | $5.17 1.57% 1.74% 350K
|
Health Technology
|
| O: -0.21%
H: 2.39%
C: -1.05%
New Variants Throw the Spotlight on Booster Shots of COVID-19 Vaccines - According to New Research from StrategyR
Published: 2022-03-10 (Crawled : 15:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: 2.52%
H: 1.67%
C: 1.67%
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
NVAX | $4.07 2.52% 2.93% 1.8M
|
Health Technology
|
| O: -1.99%
H: 2.84%
C: 0.35%
MRNA | News S | $104.46 3.01% 2.94% 2.6M
|
Health Technology
|
| O: -2.09%
H: 0.95%
C: 0.01%
covid-19 research covid vaccine
Novavax to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference
Published: 2022-02-11 (Crawled : 15:00) - biospace.com/
NVAX | $4.07 2.52% 2.93% 1.8M
|
Health Technology
|
| O: 3.19%
H: 0.0%
C: 0.0%
health thc conference svb leerink global
Novavax Confirms European Medicines Agency Review of COVID-19 Vaccine Filing for Conditional Marketing Authorization
Published: 2021-11-17 (Crawled : 15:00) - biospace.com/
NVAX | $4.07 2.52% 2.93% 1.8M
|
Health Technology
|
| O: 2.8%
H: 0.0%
C: 0.0%
covid europe vaccine covid-19
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
Published: 2020-12-28 (Crawled : 15:00) - globenewswire.com
NVAX | $4.07 2.52% 2.93% 1.8M
|
Health Technology
|
| O: -0.07%
H: 0.58%
C: -9.59%
covid vaccine phase 3 trial
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
PROK | $2.72 33.33% 24.58% 2.6M
|
Your saved searches
Save your searches and get alerts when important news are released.